The role of lamivudine versus entecavir in prevention of HCC in patients with hepatitis B virus-related cirrhosis
| Autor: | Cristina Olariu, Oana Șchiopu, Adriana Nurciu, Magdalena Popa, Dan Olteanu |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Hepatitis B virus
medicine.medical_specialty Pathology Cirrhosis medicine.diagnostic_test business.industry Lamivudine Magnetic resonance imaging Entecavir medicine.disease_cause medicine.disease Gastroenterology digestive system diseases Serology Infectious Diseases Medical microbiology Abdominal ultrasonography Internal medicine Poster Presentation Medicine business neoplasms medicine.drug |
| Zdroj: | BMC Infectious Diseases |
| ISSN: | 1471-2334 |
| DOI: | 10.1186/1471-2334-13-s1-p69 |
| Popis: | Methods We included 36 patients with hepatitis B virus related cirrhosis. Since February 2008 until now, 45% (16 patients) were treated with lamivudine and 55% (20 patients) with entecavir. The evaluation was performed every 3-4 months by clinical exam, biochemical and serological tests, and abdominal ultrasonography for all patients. Upper endoscopy, computed tomography scanning or magnetic resonance imaging were done in selective cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink